Gene-Chemical Interaction Annotations Click to see Annotation Detail View
Term | Qualifier | Evidence | With | Reference | Notes | Source | Original Reference(s) | 17alpha-ethynylestradiol | decreases expression | EXP | | 6480464 | Ethinyl Estradiol results in decreased expression of TMEM35A mRNA | CTD | PMID:17557909 | 2,3,7,8-Tetrachlorodibenzofuran | increases expression | EXP | | 6480464 | 2 more ... | CTD | PMID:32109520 | 3,4-methylenedioxymethamphetamine | decreases expression | ISO | Tmem35a (Mus musculus) | 6480464 | N-Methyl-3 and 4-methylenedioxyamphetamine results in decreased expression of TMEM35A mRNA | CTD | PMID:26251327 | 4,4'-sulfonyldiphenol | increases expression | ISO | TMEM35A (Homo sapiens) | 6480464 | bisphenol S results in increased expression of TMEM35A mRNA | CTD | PMID:27685785 | 4,4'-sulfonyldiphenol | multiple interactions | EXP | | 6480464 | [bisphenol A co-treated with bisphenol F co-treated with bisphenol S] results in decreased expression of TMEM35A mRNA | CTD | PMID:36041667 | 6-propyl-2-thiouracil | increases expression | EXP | | 6480464 | Propylthiouracil results in increased expression of TMEM35A mRNA | CTD | PMID:24780913 and PMID:36843608 | aflatoxin B1 | decreases methylation | ISO | TMEM35A (Homo sapiens) | 6480464 | Aflatoxin B1 results in decreased methylation of TMEM35A gene | CTD | PMID:27153756 | all-trans-retinoic acid | decreases expression | ISO | TMEM35A (Homo sapiens) | 6480464 | Tretinoin results in decreased expression of TMEM35A mRNA | CTD | PMID:21934132 | alpha-Zearalanol | multiple interactions | EXP | | 6480464 | [Zeranol co-treated with perfluorooctanoic acid] results in decreased expression of TMEM35A mRNA | CTD | PMID:35163327 | antirheumatic drug | increases expression | ISO | TMEM35A (Homo sapiens) | 6480464 | Antirheumatic Agents results in increased expression of TMEM35A mRNA | CTD | PMID:24449571 | benzo[a]pyrene diol epoxide I | increases expression | ISO | TMEM35A (Homo sapiens) | 6480464 | 7 more ... | CTD | PMID:20382639 | bis(2-ethylhexyl) phthalate | multiple interactions | EXP | | 6480464 | [diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisononyl phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] results in decreased expression of TMEM35A mRNA | CTD | PMID:31199487 | bisphenol A | decreases expression | EXP | | 6480464 | bisphenol A results in decreased expression of TMEM35A mRNA | CTD | PMID:25181051 | bisphenol A | multiple interactions | EXP | | 6480464 | [bisphenol A co-treated with bisphenol F co-treated with bisphenol S] results in decreased expression of TMEM35A mRNA | CTD | PMID:36041667 | bisphenol A | increases expression | EXP | | 6480464 | bisphenol A results in increased expression of TMEM35A mRNA | CTD | PMID:33296240 | bisphenol F | multiple interactions | EXP | | 6480464 | [bisphenol A co-treated with bisphenol F co-treated with bisphenol S] results in decreased expression of TMEM35A mRNA | CTD | PMID:36041667 | Butylbenzyl phthalate | multiple interactions | EXP | | 6480464 | [diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisononyl phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] results in decreased expression of TMEM35A mRNA | CTD | PMID:31199487 | carbon nanotube | decreases expression | ISO | Tmem35a (Mus musculus) | 6480464 | Nanotubes more ... | CTD | PMID:25554681 | clobetasol | increases expression | ISO | Tmem35a (Mus musculus) | 6480464 | Clobetasol results in increased expression of TMEM35A mRNA | CTD | PMID:27462272 | dibutyl phthalate | multiple interactions | EXP | | 6480464 | [diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisononyl phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] results in decreased expression of TMEM35A mRNA | CTD | PMID:31199487 | diethyl phthalate | multiple interactions | EXP | | 6480464 | [diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisononyl phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] results in decreased expression of TMEM35A mRNA | CTD | PMID:31199487 | diisobutyl phthalate | multiple interactions | EXP | | 6480464 | [diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisononyl phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] results in decreased expression of TMEM35A mRNA | CTD | PMID:31199487 | diisononyl phthalate | multiple interactions | EXP | | 6480464 | [diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisononyl phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] results in decreased expression of TMEM35A mRNA | CTD | PMID:31199487 | dorsomorphin | multiple interactions | ISO | TMEM35A (Homo sapiens) | 6480464 | [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1 more ... | CTD | PMID:27188386 | endosulfan | increases expression | EXP | | 6480464 | Endosulfan results in increased expression of TMEM35A mRNA | CTD | PMID:29391264 | furan | increases expression | EXP | | 6480464 | furan results in increased expression of TMEM35A mRNA | CTD | PMID:25539665 and PMID:27387713 | ivermectin | decreases expression | ISO | TMEM35A (Homo sapiens) | 6480464 | Ivermectin results in decreased expression of TMEM35A protein | CTD | PMID:32959892 | levonorgestrel | multiple interactions | ISO | TMEM35A (Homo sapiens) | 6480464 | [testosterone undecanoate co-treated with Levonorgestrel] results in decreased expression of TMEM35A mRNA | CTD | PMID:19074003 | methylmercury chloride | decreases expression | ISO | TMEM35A (Homo sapiens) | 6480464 | methylmercuric chloride results in decreased expression of TMEM35A mRNA | CTD | PMID:28001369 | ochratoxin A | increases expression | EXP | | 6480464 | ochratoxin A results in increased expression of TMEM35A mRNA | CTD | PMID:37162024 | ochratoxin A | decreases methylation | EXP | | 6480464 | ochratoxin A results in decreased methylation of TMEM35A gene | CTD | PMID:37162024 | oxaliplatin | multiple interactions | EXP | | 6480464 | [oxaliplatin co-treated with Topotecan] results in increased expression of TMEM35A mRNA | CTD | PMID:25729387 | oxaliplatin | increases expression | EXP | | 6480464 | oxaliplatin results in increased expression of TMEM35A mRNA | CTD | PMID:25729387 | ozone | multiple interactions | ISO | Tmem35a (Mus musculus) | 6480464 | [Air Pollutants results in increased abundance of Ozone] which results in decreased expression of TMEM35A mRNA | CTD | PMID:34911549 | p-chloromercuribenzoic acid | multiple interactions | ISO | TMEM35A (Homo sapiens) | 6480464 | [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1 and 3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of TMEM35A mRNA | CTD | PMID:27188386 | p-chloromercuribenzoic acid | decreases expression | ISO | TMEM35A (Homo sapiens) | 6480464 | p-Chloromercuribenzoic Acid results in decreased expression of TMEM35A mRNA | CTD | PMID:26272509 | perfluorooctanoic acid | multiple interactions | EXP | | 6480464 | [Zeranol co-treated with perfluorooctanoic acid] results in decreased expression of TMEM35A mRNA | CTD | PMID:35163327 | phenylmercury acetate | decreases expression | ISO | TMEM35A (Homo sapiens) | 6480464 | Phenylmercuric Acetate results in decreased expression of TMEM35A mRNA | CTD | PMID:26272509 | phenylmercury acetate | multiple interactions | ISO | TMEM35A (Homo sapiens) | 6480464 | [NOG protein co-treated with Phenylmercuric Acetate co-treated with dorsomorphin co-treated with 4-(5-benzo(1 and 3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of TMEM35A mRNA | CTD | PMID:27188386 | SB 431542 | multiple interactions | ISO | TMEM35A (Homo sapiens) | 6480464 | [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1 more ... | CTD | PMID:27188386 | sodium arsenite | decreases expression | ISO | Tmem35a (Mus musculus) | 6480464 | sodium arsenite results in decreased expression of TMEM35A mRNA | CTD | PMID:37682722 | Soman | increases expression | EXP | | 6480464 | Soman results in increased expression of TMEM35A mRNA | CTD | PMID:19281266 | sunitinib | decreases expression | ISO | TMEM35A (Homo sapiens) | 6480464 | Sunitinib results in decreased expression of TMEM35A mRNA | CTD | PMID:31533062 | testosterone undecanoate | multiple interactions | ISO | TMEM35A (Homo sapiens) | 6480464 | [testosterone undecanoate co-treated with Levonorgestrel] results in decreased expression of TMEM35A mRNA | CTD | PMID:19074003 | testosterone undecanoate | decreases expression | ISO | TMEM35A (Homo sapiens) | 6480464 | testosterone undecanoate results in decreased expression of TMEM35A mRNA | CTD | PMID:19074003 | topotecan | increases expression | EXP | | 6480464 | Topotecan results in increased expression of TMEM35A mRNA | CTD | PMID:25729387 | topotecan | multiple interactions | EXP | | 6480464 | [oxaliplatin co-treated with Topotecan] results in increased expression of TMEM35A mRNA | CTD | PMID:25729387 | trichostatin A | increases expression | ISO | TMEM35A (Homo sapiens) | 6480464 | trichostatin A results in increased expression of TMEM35A mRNA | CTD | PMID:24935251 | trichostatin A | multiple interactions | ISO | TMEM35A (Homo sapiens) | 6480464 | [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1 and 3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of TMEM35A mRNA | CTD | PMID:27188386 | trichostatin A | decreases expression | ISO | TMEM35A (Homo sapiens) | 6480464 | trichostatin A results in decreased expression of TMEM35A mRNA | CTD | PMID:24935251 and PMID:26272509 | triptonide | increases expression | ISO | Tmem35a (Mus musculus) | 6480464 | triptonide results in increased expression of TMEM35A mRNA | CTD | PMID:33045310 | tunicamycin | decreases expression | ISO | TMEM35A (Homo sapiens) | 6480464 | Tunicamycin results in decreased expression of TMEM35A mRNA | CTD | PMID:22378314 | valproic acid | affects expression | ISO | TMEM35A (Homo sapiens) | 6480464 | Valproic Acid affects the expression of TMEM35A mRNA | CTD | PMID:25979313 | valproic acid | decreases expression | ISO | TMEM35A (Homo sapiens) | 6480464 | Valproic Acid results in decreased expression of TMEM35A mRNA | CTD | PMID:28001369 | valproic acid | increases expression | ISO | TMEM35A (Homo sapiens) | 6480464 | Valproic Acid results in increased expression of TMEM35A mRNA | CTD | PMID:24935251 | vinclozolin | increases methylation | EXP | | 6480464 | vinclozolin results in increased methylation of TMEM35A gene | CTD | PMID:31682807 | vorinostat | multiple interactions | ISO | TMEM35A (Homo sapiens) | 6480464 | [NOG protein co-treated with Vorinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1 and 3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of TMEM35A mRNA | CTD | PMID:27188386 | |